EBSAM
NTLA icon

Eubel Brady & Suttman Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13
Closed -$1K – 251
2021
Q2 		$1K Buy
+13
New +$1.01K ﹤0.01% 632

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's NTLA Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 13 shares — an estimated $1K sold.

Eubel Brady & Suttman Asset Management first reported a position in NTLA in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 13 Intellia Therapeutics shares in Q3 2021, an estimated $1K.
  • Eubel Brady & Suttman Asset Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Intellia Therapeutics position peaked at $1K in Q2 2021.
  • 364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.